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Background. Acute respiratory insufficiency (ARl) with alveolar hypoventilation or incapacitating dyspnoea but 
without peripheral muscle involvement can be an early manifestation of respiratory involvement in amyotrophic 
lateral sclerosis (ALS). Some of these patients benefit from assisted ventilation. The object of this study was to 
analyse the results of long-term mechanical ventilation (LTMV) in ten patients with ALS. 
Methods. A retrospective analysis of intensive care unit (ICU) or ambulant patients with ALS who underwent 
LTMV in a conventional hospital ward was performed. Erect and supine spirometry, blood gas analysis and pulse 
oximetry were performed before the start and during the course of ventilation. 
Results. Ten patients on LTMV were included. Four from the ICU were ventilated via tracheostomy, and six 
ambulant patients had non-invasive (nasal) ventilation. In all cases, ventilation was performed in a conventional 
hospital ward. The ambulant patients improved symptomatically during ventilation, confirmed by measurement of 
gas exchange and of SaO, by continuous pulse oximetry. Three of the ten patients survive in long-term care - two 
with nasal and one with tracheostomy ventilation. 
Conclusions. LTMV outside ICU was possible in ten patients, seven of whom returned home. Returning home is 
very difficult for patients dependent on a ventilator who lack family support. 
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Introduction 
Amyotrophic lateral sclerosis is the most common form of 
the so-called motor neurone diseases. It is characterized by 
the loss and degeneration of upper and lower motor neu- 
rones, presenting initially with spasticity and hyper-reflexia 
and later with fasciculations, weakness and loss of muscle 
strength. The course of the disease is variable but it is 
estimated that survival at 3 years is 50% (l), although 10% 
live for up to 10 years (2). 
Respiratory insufficiency usually manifests itself late in 
the course of ALS. However, cases have been described in 
which the first manifestation of the disease was dyspnoea 
with acute respiratory insufficiency (ARI) and alveolar 
hypoventilation because of diaphragmatic involvement 
(3-5) without involvement of peripheral muscles (6). In 
some of these patients with severe symptoms, ventilatory 
support has been proposed. Others have been intubated 
and ventilated without knowledge of the neurological diag- 
nosis. The decision to ventilate a patient with ALS is 
complex, given the rapid evolution of the disease in the 
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majority of cases, as the patient may become completely 
dependent on the ventilation, and it does not influence the 
underlying course of the disease. 
We present our experience of long-term mechanical 
ventilation (LTMV) of patients with ALS. 
Methods 
SUBJECTS 
Since 1988, LTMV has been prescribed for ten patients with 
ALS. In every case, the neurological diagnosis was estab- 
lished by electromyography. The criteria for inclusion were: 
(a) patients ventilated in ICU for some time who would not 
tolerate disconnection of the ventilator for more than 24 h, 
and (b) patients who had moderate involvement of periph- 
eral muscles, that is, could walk and maintain an active life, 
but had incapacitating dyspnoea, orthopnoea which made 
lying down impossible, or diurnal hypercapnia (PaCO, 
~45 mmHg. 
PROTOCOL 
In every case ventilation was performed in a conventional 
hospital ward. The machines used were home volume- 
controlled ventilators (PLV-100, Life Carem), Companion 
2801 (Puritan Bennett@) or pressure-support ventilators 
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TABLE 1. Basal characteristics of the ten patients 
Age (years) 
Sex (M/F) 
Months of ALS evolution 
PaO, (mmHg) (Fro,)* 
PaCO, (mmHg) (Fro, 0.2)* 
FVC sitting (ml)* 
FVC sitting (% theoretical) 
FEV, sitting (ml)* 
FEV, sitting (% theoretical) 
FVC supine (ml)* 
59.2 i 1.1 
812 
17.0 f 12.3 
78.3 * 13.1 
52.5 + 8.1 
1830 f 997 
50.7 f 19.9 
1478 zk 918 
50 k 12.4 
1150&627 
*Data corresponding to the six ambulatory patients. 
(BiPAP S/T, Respironics In@). These were connected to 
tracheostomy tubes or nasal masks which were made-to- 
measure silicone (7) or commercial masks (Respironics’m). 
Wherever possible, the following investigations were per- 
formed before commencing ventilation: arterial blood gas 
analysis when breathing room air, sitting and supine forced 
spirometry (FVC, FEV,, FEC/FEV,%) and nocturnal pulse 
oximetry (Pulsox 7, Minolta@) when breathing room air. 
Once ventilation was in progress, we checked its efficacy by 
carrying out arterial blood gas analysis with the patient 
awake, and continuous pulse oximetry during nocturnal 
ventilation. We considered that ventilation was effective if it 
produced an improvement in symptoms, corrected hyper- 
capnia (PaCO, ~45 mmHg when awake or a relative 
decrease in PaCO, with improvement in pH up to 7.40), 
and if nocturnal pulse oximetry without oxygen showed an 
SpO, of greater than 90% for more than 85% of the night. 
STATISTICAL ANALYSIS 
A chi-squared analysis was used to compare proportions, 
and the t-test was used to compare measurements. Values 
of PcO.05 were considered significant. 
Results 
PATIENTS 
Table 1 shows the characteristics of the ten patients pre- 
scribed LTMV. Arterial blood gases and pulmonary func- 
tion tests were performed in the six ambulatory patients. 
The spirometic data showed a restrictive disorder with a 
significant fall in FVC (37%) in the supine position, 
suggesting diaphragmatic impairment. 
CONDITION OF THE PATIENTS WHEN 
COMMENCING LTMV 
Four patients were in the ICU because of acute respiratory 
insufficiency requiring mechanical ventilation via tracheos- 
tomy and had failed attempts at weaning. One was receiv- 
ing nocturnal ventilation only. Three were being ventilated 
almost continuously. The average stay in the ICU was 1.3 
months (0.5-5.0 months). At the time LTMV was pro- 
posed, these four patients were moved to a conventional 
hospital ward. The other six were outpatients for whom 
LTMV was prescribed during a programmed stay in hospi- 
tal. The six had orthopnoea of between 2 and 6 months 
duration. One was completely incapacitated when lying 
down. Four had alterations of the voice due to shortness of 
breath, and one had dysphagia to liquids. 
NOCTURNAL BASAL PULSE OXIMETRY AND 
SPIROMETRY 
This was performed in the five ambulant patients who could 
tolerate lying down. The results of pulse oximetry con- 
firmed that they had an SpO, of less than 90% for 62.3% 
(range 7-97%) of the time, the SpO, falling to between 85 
and 90% in all but two cases who desaturated below 85%. 
VENTILATION CHARACTERISTICS 
All the patients from the ICU kept their tracheostomy, and 
a volume-controlled ventilator was used. The ambulant 
patients had nasal masks. Three had a made-to-measure 
mask and volume-controlled ventilator, three had a 
standard mask and a high-flow, positive-pressure unit 
(BiPAP@). Two of the patients using BiPAP later required 
a change to a volume-controlled ventilator and a made-to- 
measure mask to increase the efficiency of ventilation. 
LTMV was given for an average of 12.2 months (1.5 to 47.5 
months). 
VENTILATION EFFECTIVENESS 
The four patients from the ICU continued ventilation with 
home units in the conventional hospital ward, demon- 
strating that this was as effective as ventilation in the ICU. 
A clinical improvement was observed in the ambulant 
patients from the start of LTMV; they could better tolerate 
lying down, and nocturnal pulse oximetry during ventila- 
tion showed an SpO, of less than 90% only 8% (range 
0.6-32%) of the time. Comparing these figures with those 
of the five patients who had baseline pulse oximetry 
measurements shows that the time during which the SpO, 
is less than 90% is significantly lower during mechanical 
ventilation (P<O.O05). Gas exchange also improved 
during ventilation. The PaO, (mean + SD) increased 
from 78.3 f 3.1 mmHg when breathing atmospheric air 
to 87.2 + 9.0 mmHg during ventilation. The PaCO, fell 
from 52.5 f 8.1 mmHg when breathing atmospheric air 
to 43.2 f 8.9 mmHg during ventilation. 
RETURNING HOME 
In seven cases, the patients were able to continue HMV 
(home mechanical ventilation). In two cases there was not 
enough family support to allow this, so these patients were 
transferred to a non-hospital centre. One patient died in 
hospital while adapting to ventilation. 
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TABLE 2. Causes of death in the ventilated patients 
n-IPPV t-IPPV Total 
Cause of death (four cases) (three cases) (seven cases) 
ALS evolution 214 213 411 
Sudden death l/4 l/3 2/l 
Suicide l/4 l/7 
n-IPPV=nasal mask positive-pressure ventilation. 
t-IPPV=tracheostomy positive-pressure ventilation. 
FOLLOW UP 
Overall survival of our patients with ALS who required 
ventilatory support was 60% at 6 months and 30% at 12 
months. The causes of death are listed in Table 2. The 
patient who committed suicide maintained the mobility of 
his arms and used a firearm. The term ‘ALS evolution’ 
refers to progression of the muscular weakness with reduc- 
tion in free time of ventilation and development of bulbar 
impairment. In this situation, mechanical ventilation via a 
nasal mask was not sufficiently effective. Although the 
tracheostomy was proposed at that moment, and the 
patients were informed about the possible improvement of 
survival with this procedure, it was refused in all cases. 
When symptoms of respiratory insufficiency appeared, the 
palliative care with sedative treatments, including mor- 
phine, were established. In the patients with tracheostomy 
we do not know the exact cause of death because one 
moved to another city and the other was admitted to a 
hospice. Three patients with ALS are still alive, two on 
home ventilation and one in long-term care, having had 
ventilation for between 3 and 47.5 months. The two 
patients on home ventilation use made-to-measure silicone 
nasal masks, and the other is ventilated via a tracheostomy. 
Discussion 
There is a progressive reduction in vital capacity (VC) as 
ALS develops, clearly related to muscular weakness (S), but 
symptoms such as resting dyspnoea or orthopnoea usually 
appear in very advanced phases of the disease (9). As the 
respiratory muscles become involved, they become incapa- 
ble of generating the airflow required to mobilize the 
secretions, and the cough becomes inefficient. There is 
frequent involvement of the upper airway, especially where 
there is bulbar disease (10). Gas exchange impairment is a 
late finding, usually observed when the VC falls by about 
20% or less of the predicted value (2). 
In spite of the pre-eminence of respiratory symptoms, 
only 5% of patients in Illinois (U.S.A.) with ALS are 
chronically ventilated, an incidence of two patients per 
million inhabitants. This percentage varies greatly between 
centres, from 1.6 to 14.3%, reflecting the different attitudes 
of doctors towards LTMV in patients with ALS (11). 
Some authors have suggested that the use of intermittent 
negative-pressure ventilation using a poncho is efficient and 
cheaper (12). However, positive-pressure ventilation using 
volumetric ventilators is the most widely used and the safest 
for the patient (13,14). Nogueras et al. (1.5) described HMV 
in a patient with ALS for the first time in Spain, modifying 
a model Mark-7 respiratory to suit the patient. The avail- 
ability of small volumetric ventilators allows the use of 
HMV in these cases. Our patients needed volume- 
controlled ventilators because the pressure-support units do 
not allow minute volume increments and do not have 
alarms. Two of the three cases who started LTMV using 
BiPAP were changed to volume-controlled ventilators, 
In every case, LTMV was performed in conventional 
hospital wards. In ambulant patients, ventilation corrects 
orthopnoea, improves gas exchange and corrects nocturnal 
desaturation. In our experience seven of the ten patients 
who started LTMV were able to return home on HMV. 
Salamand et al. (16) achieved HMV in a third of patients 
with ALS and LTMV. Returning home depends .on the 
neurological involvement of the patient, family support and 
the available medical resources. Our resources are limited. 
In our centre we have prescribed HMV to more than 200 
patients and we have developed a home support pro- 
gramme from the hospital. However, neuromuscular 
patients, and especially those affected by ALS, may require 
more continuous and specific attention than our pro- 
gramme can provide and there are no other specific 
resources or centres for these patients. The three patients 
who could not return home were immobile (tetraparetic), 
had tracheostomies and could not be weaned from the 
ventilator. Two were moved to long-term care, and the 
third died in a conventional hospital ward, outside the ICU. 
The discussion about therapeutic alternatives should not 
focus solely on the ICU and the home. The object should be 
to avoid long stays in the ICU and find the ideal place 
to treat the patient, in a conventional hospital ward, a 
long-stay hospital, in long-term care or, where possible, at 
home (17). 
The survival of patients with ALS on LTMV is very 
variable. Salamand et al. (18) describe survival of 1 year in 
patients ventilated via a tracheostomy, while Oppenheimer 
(19) describes survival of 85% in 29 consecutive patients, 
suggesting that success depends largely on available 
resources. Our purpose when LTMV is prescribed is not 
only to increase survival but to improve the quality of life. 
When the patients and their families have received informa- 
tion and the treatment has been planned, this aim has been 
achieved. 
One must remember that patients with ALS on LTMV 
will progressively lose mobility and will require help for all 
the activities of daily life. This dependency on another 
person stops many patients from returning home. More- 
over, although non-invasive ventilation with a nasal mask 
may be satisfactory initially, dependency on the ventilator 
will gradually increase, and we have to consider tracheos- 
tomy. None of the patients who started HMV with a nasal 
mask later accepted tracheostomy as they were aware of the 
evolution and outcome of their illness. In some countries 
(20) there is legal support for withdrawing invasive mech- 
anical ventilation when desired. The advantages of non- 
invasive mechanical ventilation, which requires fewer 
resources and provides the patients with the opportunity of 
deciding how to continue mechanical ventilation as ALS 
progresses, should be pointed out. Bach (21) reports the 
use, in 2.5 patients, of non-invasive ventilation which avoids 
or delays the use of tracheostomy. 
None of the patients who required admission to the ICU 
and ventilation via tracheostomy had decided in favour of 
ventilation before the AR1 episode. Moss et al. (11) also 
report that only a minority of patients with ALS had 
decided in favour of ventilation before the onset of respir- 
atory insufficiency, and many patients had been intubated 
in the emergency department. These decisions in critical 
situations should be avoided in ALS patients. Hence, the 
patient and family should be carefully informed so that the 
treatment can be planned as the disease progresses. The 
subjects should understand the benefits and limitations of 
invasive and non-invasive mechanical ventilation and also 
know the possible choice of palliative care. 
Despite the difficulties, LTMV can benefit a minority of 
patients with ALS, especially if they have support from 
their families. In all cases, we must try to avoid emergency 
ventilation, so it is fundamentally important to inform the 
patient adequately so that decisions can be made before 
AR1 occurs (22). It must be made clear to the patient that 
LTMV will not change the natural history of ALS and that, 
although they may need the ventilator only during the night 
at first, dependency will gradually increase. 
There are no firm indications for LTMV in patients with 
ALS, but it is more likely that good results will be obtained 
in patients who are well motivated, with slowly evolving 
disease, with a family which understands the problem and is 
willing to help, and where there are the necessary resources 
(23). Likewise, it is reasonable to propose LTMV for 
patients whose first manifestation of neurological disease is 
ARI, persistent hypercapnia or for those with incapacitat- 
ing respiratory symptoms with little involvement of pcriph- 
era1 muscles. Presently, LTMV is not a treatment for all 
patients in very advanced stages of ALS. Finally, it is very 
important to focus attention outside the hospital to allow 
these patients to return home. 
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